UPCC 19922 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 852079
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
